Arcturus’ unlocked nucleomonomer agents (UNAs) can improve the in vivo efficiency of small interfering RNA (siRNA)-mediated gene silencing and potentially improve the efficiency of messenger RNA (mRNA)-mediated protein replacement. UNAs are RNA analogues in which the C2′-C3′ bond of the ribose ring is absent (see figure below).
One or more UNAs can be positioned strategically along a nucleic acid strand to manipulate the chemical properties of the molecule. Addition of a single UNA in siRNA therapeutics can enable more efficient suppression of target protein production.
June 13, 2019
Arcturus Therapeutics Announces Redomiciliation to the United States as a Delaware Corporation
May 20, 2019
Arcturus Therapeutics Presenting Data for ARCT-810 and the Arcturus mRNA + LUNAR® Technology Platform at the 2019 Annual Meeting of TIDES: Oligonucleotide and Peptide Therapeutics
May 13, 2019
Arcturus Therapeutics Announces First Quarter Financial Results and Provides a Corporate Update